In search of Neuraltus’ Ari Azhir or just answers!

I haven’t been able to find out any more details on the press release from Neuraltus’ regarding their funding for a new Gaucher’s Disease treatment.  I could be wrong in assuming, but since they work in neurodenerative diseases that they must be working on something for type 2 or type 3. 

I have had no luck yet finding out.  There doesn’t seem to be a website for Neuraltus that I can find.  I have emailed two of the founders at their respective hospitals.  I have also emailed two of the venture capital partners.  I cannot find any contact information for the CEO they mention in the article, Ari Azhir.   I found a phone number for the company Azhir works for, but when I called it, it was disconnected (probably old).  I’ll give these emails a couple of days.  Then, if I don’t get an answer, I will start calling around. 

I just need to know if this is hope for GD2 or GD3… even if they can’t give me details yet, just let me know which GD it is for.  If anyone can help find out, I would so appreciate the assistance!